James Grainer - Taxus Cardium CFO Chairman
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Insider
James Grainer is CFO Chairman of Taxus Cardium Pharmaceuticals
| Age | 68 |
| Phone | 858 414 1477 |
| Web | https://genebiotherapeutics.com |
Taxus Cardium Management Efficiency
The company has return on total asset (ROA) of (2.619) % which means that it has lost $2.619 on every $100 spent on assets. This is way below average. Taxus Cardium's management efficiency ratios could be used to measure how well Taxus Cardium manages its routine affairs as well as how well it operates its assets and liabilities.Taxus Cardium Pharmaceuticals currently holds 1.26 M in liabilities. Taxus Cardium Pharma has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Taxus Cardium until it has trouble settling it off, either with new capital or with free cash flow. So, Taxus Cardium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Taxus Cardium Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Taxus to invest in growth at high rates of return. When we think about Taxus Cardium's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Samik MD | Cabaletta Bio | N/A | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Heather MSc | Cabaletta Bio | N/A | |
| Jack Anders | Revolution Medicines | 48 | |
| Melissa Brody | Kymera Therapeutics | N/A | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Margaret JD | Revolution Medicines | 61 | |
| Thierry Bilbault | Akebia Ther | 65 | |
| Jonathan MD | Erasca Inc | 52 | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| Martha OConnor | Cabaletta Bio | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Sunil MD | Sana Biotechnology | 54 | |
| Path FRCP | Revolution Medicines | 61 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Anup MBA | Cabaletta Bio | 46 | |
| Bernard JD | Sana Biotechnology | 69 | |
Management Performance
| Return On Asset | -2.62 |
Taxus Cardium Pharma Leadership Team
Elected by the shareholders, the Taxus Cardium's board of directors comprises two types of representatives: Taxus Cardium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taxus. The board's role is to monitor Taxus Cardium's management team and ensure that shareholders' interests are well served. Taxus Cardium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taxus Cardium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Shebuski, Chief Officer | ||
| Christopher Reinhard, Co-Founder, CEO and President Treasurer and Executive Director | ||
| Lois Chandler, Chief Officer | ||
| Duane Linstrom, G Counsel | ||
| James Grainer, CFO Chairman | ||
| Kelly Scott, VP Inc |
Taxus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Taxus Cardium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |